Sandy Srinivas, MD, describes an experience in which a patient with renal cell carcinoma achieved a complete response following therapy with ipilimumab and nivolumab. Dr Srinivas notes that the results of the CheckMate 214 study give her hope that her patient will maintain a complete response.